2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

2:30PM-4:00PM: Abstract Number: 859

Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis

3S081: SLE – Clinical I: Clinical Trials (857–862)

2:30PM-4:00PM: Abstract Number: 846

MACE and VTE Across Multiple Upadacitinib Studies in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program

3S080: RA – Treatments I: Safety and Outcomes (845–850)

2:30PM-4:00PM: Abstract Number: 831

Maintaining Musculoskeletal Health: A Randomized Controlled Prevention Trial Amongst People at High Risk of Developing Chronic Widespread Pain

3S075: Fibromyalgia & Other Clinical Pain Syndromes (827–832)

2:30PM-4:00PM: Abstract Number: 857

Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients

3S081: SLE – Clinical I: Clinical Trials (857–862)

2:30PM-4:00PM: Abstract Number: 813

Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome

3S077: Pediatric Rheumatology – Basic Science (810–814)

2:30PM-4:00PM: Abstract Number: 811

Monomethyl Fumarate as a Novel Therapy for Macrophage Activation Syndrome: Mechanism of Action in an Animal Model

3S077: Pediatric Rheumatology – Basic Science (810–814)

2:30PM-4:00PM: Abstract Number: 842

Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis – Lung Disease

3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)

2:30PM-4:00PM: Abstract Number: 856

MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?

3S083: Spondyloarthritis Including Psoriatic Arthritis – Clinical I: Imaging in Axial Spondyloarthritis & Psoriatic Arthritis (851–856)

2:30PM-4:00PM: Abstract Number: 870

Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)

3S085: Vasculitis – ANCA-Associated I (869–874)

2:30PM-4:00PM: Abstract Number: 836

Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results

3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)

2:30PM-4:00PM: Abstract Number: 824

Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients

3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)

2:30PM-4:00PM: Abstract Number: 877

Rheumatoid Arthritis Patients’ Perspectives on Tapering of Biologics: A Qualitative Study

3S092: New Approaches to Old Diseases (875–879)

2:30PM-4:00PM: Abstract Number: 849

Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database

3S080: RA – Treatments I: Safety and Outcomes (845–850)

2:30PM-4:00PM: Abstract Number: 848

Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis

3S080: RA – Treatments I: Safety and Outcomes (845–850)

2:30PM-4:00PM: Abstract Number: 867

Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial

3S084: Systemic Sclerosis & Related Disorder – Clinical I: Therapeutics & Outcomes (863–868)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].